German chemical and pharma group Merck KGaA has acknowledged that it is in talks to buy US biotech SpringWorks, but cautioned there is no guarantee a deal will be forthcoming. Merck said in a ...

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks about a possible takeover, a new FDA approval could have sweetened the deal. Stamford, Connecticut-based SpringWorks ...

BofA lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $84 from $87 and keeps a Buy rating on the shares. While Q1 ...

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Springworks Therapeutics (SWTX – Research Report) today and set a price target of $84.00. The company’s shares ...

So should SpringWorks Therapeutics (NASDAQ:SWTX) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of ...

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against other high growth forever dividend stocks. Dividend stocks have trailed the broader market over the ...

Safety and Activity of Fibroblast Growth Factor Receptor Inhibitors in Advanced Malignancies: A Pooled Analysis of Early-Phase Clinical Trials A comprehensive search of PubMed/MEDLINE and EMBASE was ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...